Abstract
Ovarian cancer continues to be a major cause of morbidity and mortality in women. Antiangiogenic treatments have emerged as a promising strategy to treat ovarian cancer. This article reviews the rationale supporting the use of antiangiogenic treatments in ovarian cancer, the clinical development of this group of drugs and the toxicities specific to this modality of treatment.
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Endothelial Cells / drug effects
-
Endothelial Cells / physiology
-
Female
-
Humans
-
Neovascularization, Pathologic / drug therapy
-
Ovarian Neoplasms / blood supply
-
Ovarian Neoplasms / drug therapy*
-
Ovary / blood supply
-
Receptors, Vascular Endothelial Growth Factor / antagonists & inhibitors
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Vascular Endothelial Growth Factor A
-
Bevacizumab
-
Receptors, Vascular Endothelial Growth Factor